The global health and economic value of COVID-19 vaccination
We provide the first estimates of the broad value of CV incorporating GDP, QALY and direct and indirect cost impacts. Through December 2021, CV produced significant health and economic value, represented strong value for money and produced significant macroeconomic benefits that should be considered in vaccine evaluation.
Authors
- J.P. Sevilla (ORCID: https://orcid.org/0000-0001-9807-657X)
- Daria Burnes (ORCID: https://orcid.org/0000-0002-8624-1344)
- Jennifer L. Nguyen (ORCID: https://orcid.org/0000-0002-4064-0227)
- Manuela Di Fusco (ORCID: https://orcid.org/0000-0003-0079-7331)
- David E. Bloom (ORCID: https://orcid.org/0000-0003-3731-3345)
- Moe H Kyaw (ORCID: https://orcid.org/0009-0000-9111-7666)
- Jingyan Yang
- Joseph S Knee (ORCID: https://orcid.org/0000-0001-5300-4206)
Institutions
- Harvard University (US)
- Pfizer (United States) (US)
- Health Decisions (United States) (US)
Publication Details
- Journal
- BMJ Global Health
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1136/bmjgh-2024-015031
- Citations
- 5
- Primary Topic
- COVID-19 epidemiological studies
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Pfizer